Jakavi (Ruxolitinib)
ruxolitinib 5 mg tablet, 56 · ORAL · PBS code 10614P
AUTHORITY_REQUIREDWhat it costs
AU$2256.25 PBS-determined price per 112 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2016-02-01.
- • Repeats: 0.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
High risk and intermediate-2 risk myelofibrosis
Initial treatment
The condition must be either: (i) primary myelofibrosis, (ii) post-polycythaemia vera myelofibrosis, (iii) post-essential thrombocythaemia myelofibrosis, confirmed through a bone marrow biopsy report; AND
The treatment must be the sole PBS-subsidised JAK inhibitor therapy for this condition.
Details of the following must be documented in the patient's medical records:
(a) the bone marrow biopsy report confirming diagnosis of myelofibrosis (date, unique identifying number/code or provider number); and
(b) a classification of risk of myelofibrosis according to either the IPSS, DIPSS, or the Age-Adjusted DIPSS.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Intermediate-1 risk myelofibrosis
Initial treatment
The condition must be either: (i) primary myelofibrosis, (ii) post-polycythaemia vera myelofibrosis, (iii) post-essential thrombocythaemia myelofibrosis, confirmed through a bone marrow biopsy report; AND
Patient must have severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; or
Patient must have intolerance to prior treatment with a JAK inhibitor for this condition; AND
The treatment must be the sole PBS-subsidised JAK inhibitor therapy for this condition.
Details of the following must be documented in the patient's medical records:
(a) the bone marrow biopsy report confirming diagnosis of myelofibrosis (date, unique identifying number/code or provider number); and
(b) a classification of risk of myelofibrosis according to either the IPSS, DIPSS, or the Age-Adjusted DIPSS.
Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.